Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
Analyst Reports
Investor Newsletters
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
ASX Announcements
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
Analyst Reports
Investor Newsletters
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2021
2020
2019
2018
10-Sep-2021
Notification of cessation of securities - KZA
9-Sep-2021
Notification regarding unquoted securities - KZA
2-Sep-2021
Kazia's EVT801 phase I trial receives regulatory approval
2-Sep-2021
Shareholder information - amendment
30-Aug-2021
Change in Directors interests
26-Aug-2021
Kazia Annual Report to shareholders
26-Aug-2021
Kazia Corporate Governance Statement
26-Aug-2021
Kazia Appendix 4G
26-Aug-2021
Kazia Appendix 4E
16-Aug-2021
Kazia corporate presentation
1
2
3
4
5
Next
